Results 41 to 50 of about 1,330 (154)

Use of Andexanet Alfa for Factor Xa Inhibitor Reversal in US Verified Trauma Centers: A National Survey

Clinical and Applied Thrombosis/Hemostasis
Direct oral factor Xa inhibitors are replacing vitamin K-dependent antagonists as anticoagulation treatment in many clinical scenarios. Trauma centers are noting an increase in patients presenting on these medications.
Charles Fasanya MD, FRCS FACS, Abenámar Arrillaga MD FACS FCCP, Catherine Caronia MD, MBA, Lauren Rothburd BS, Tenzing Japhe BA, Younghee Hahn BS, Paul Joseph BS, Dajana Reci BA, Patricia Eckardt PhD, RN, FAAN   +8 more
doaj   +1 more source

Safety and Efficacy of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Cerebrovascular Ischemic Outcomes in Non‐Valvular Atrial Fibrillation: A Systematic Review and Meta‐Analysis

Clinical Cardiology, Volume 49, Issue 4, April 2026.
Direct Oral Anticoagulants (DOACs) were associated With lower rates of cerebrovascular ischemic events and major bleeding compared With Vitamin K antagonists in non‐valvular atrial fibrillation, With similar mortality. These findings support DOACs as the preferred anticoagulant strategy for stroke prevention in contemporary clinical practice.
Anam Nasir, Naqash Anwar, Abdullah Bin Kamran, Ayesha Muhammad, Ali Haider, Muhammad Mubashar, Fatima Tariq, Mostafa Helou, Besher Shami   +8 more
wiley   +1 more source

Excessive Apixaban Concentrations in a Bleeding Patient Treated With Pharmacological Reversal and Extracorporal Removal—A Case Report

Pharmacology Research &Perspectives, Volume 14, Issue 2, April 2026.
Excessive apixaban concentrations in a bleeding patient leading to impaired coagulation and treatment with pharmacological reversal and extracorporal removal. ABSTRACT In trauma, even therapeutic apixaban levels can significantly exacerbate bleeding.
Richard Felix Kraus, Johanna Rosenberger, Alexander Dejaco, Michael Paal, Christina Hart, Ralph Burkhardt, Martin Georg Kees   +6 more
wiley   +1 more source

Measuring Direct Oral Anticoagulant (DOAC) Levels: Applications, Limitations, and Future Directions

International Journal of Laboratory Hematology, Volume 48, Issue 2, Page 250-258, April 2026.
ABSTRACT Introduction There are important challenges with the measurement and interpretation of direct oral anticoagulant (DOAC) anticoagulant effect including a lack of therapeutic ranges, inaccuracy of routinely available coagulation assays, lack of established thresholds for clinically significant effect, and uncertainty about how to apply the ...
Siraj Mithoowani, Chee Wee Tan, Deborah M. Siegal   +2 more
wiley   +1 more source

Asundexian Versus Apixaban in Patients With Atrial Fibrillation

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background Anticoagulation therapy is central to the prevention of thromboembolic disorders but is limited by bleeding complications associated with traditional agents such as warfarin and direct oral anticoagulants (DOACs). Factor XIa inhibition has emerged as a novel strategy aimed at reducing thrombotic risk while preserving hemostasis ...
Zara Saeed, Syeda Ariba Zehra, Sumyya Tariq, Rocio Pun Zumaran, Mounika Kotte, Zeeshan Hameed, Neeraj Joshi, Pushpa Kumari, Kanta Kumari, Awais Habib, Fawad Talat, Osama Taj, Jahanzeb Malik, Abida Perveen   +13 more
wiley   +1 more source

Andexanet alpha-induced heparin resistance treated by nafamostat mesylate in a patient undergoing total aortic arch repair for Stanford type A acute aortic dissection: a case report

JA Clinical Reports
Background Andexanet alfa, an anti-Xa inhibitor antagonist, induces heparin resistance. Here, we report a case of successful management of cardiopulmonary bypass with andexanet alfa-induced heparin resistance using nafamostat mesylate.
Yasuhito Suzuki, Mutsuhito Kikura, Shingo Kawashima, Tetsuro Kimura, Yoshiki Nakajima   +4 more
doaj   +1 more source

Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values

Clinical and Applied Thrombosis/Hemostasis, 2019
Recombinant coagulation factor Xa (FXa), inactivated Zh-zo, also known as andexanet alfa (AA), is a modified version of human FXa that has been developed to neutralize FXa inhibitors.
Fakiha Siddiqui BDS, Alfonso Tafur MD, Lorenzo Storino Ramacciotti BS, Walter Jeske PhD, Debra Hoppensteadt PhD, Eduardo Ramacciotti MD, PhD, Omer Iqbal MD, FACC, FESC, Jawed Fareed PhD   +7 more
doaj   +1 more source

Neck‐vein thrombosis during spaceflight

British Journal of Clinical Pharmacology, Volume 92, Issue 1, Page 24-34, January 2026.
Spaceflight imposes unique environmental challenges, including weightlessness, increased radiation exposure and confinement, which can lead to unexpected health effects. One such example is neck‐vein thrombosis, a condition rarely seen on Earth without predisposing factors such as venous catheters or infections.
Ulrich Limper, Jens Jordan
wiley   +1 more source

Predictors of Intracranial Hemorrhage Volume Expansion in Patients Receiving Factor Xa Inhibitors in ANNEXA‐4: Time and Severity Matter Most

Stroke: Vascular and Interventional Neurology
Background Andexanet alfa, a specific reversal agent for factor Xa inhibitors, resulted in effective hemostasis in 79% of patients with intracranial bleeding in the ANNEXA‐4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa ...
Mauricio Concha, Lizhen Xu, MacKenzie Horn, Tomoyuki Ohara, Juliet Nakamya, Jan Beyer‐Westendorf, Ashkan Shoamanesh, Alexander Cohen, Per Ladenvall, Stuart J. Connolly, Andrew M. Demchuk   +10 more
doaj   +1 more source

Intracerebral Hemorrhage: Advances, Knowledge Gaps, and Future Directions

MedComm, Volume 6, Issue 11, November 2025.
This review provides a comprehensive synthesis of current research on the epidemiology, pathophysiological mechanisms, imaging characteristics, treatment delays, clinical management strategies, neural repair, and prognostic prediction of intracerebral hemorrhage (ICH).
Tao Liu, Weiwei Jiang, Minzhi Zhang, Shangzhi Xiong, Linan Chen, Xiaoying Chen, Rongcai Jiang   +6 more
wiley   +1 more source